Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03905811
Other study ID # 201902772
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 24, 2019
Est. completion date November 18, 2020

Study information

Verified date May 2022
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.


Description:

This will be a single center, randomized, double-blind, controlled, pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (MG) daily for patients with PD. The primary goal of this study is to assess the safety and tolerability of TZ in patients with PD. This is a pilot study and is not powered to assess efficacy of this medication. Our hope is that this study will guide future studies of this (and similar) medications for the disease modification of PD. This study is also aimed to learn more about how patients with produce and use energy and if TZ can help to reverse energy deficits that appear in PD.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date November 18, 2020
Est. primary completion date June 5, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 90 Years
Eligibility Inclusion Criteria: - Men or women aged 40 and older with the diagnosis of idiopathic PD per UK Brain Bank criteria - Hoehn-Yahr Stage I-III, on stable dopaminergic treatment regimen for =4 weeks prior to baseline. Exclusion Criteria: - Subjects unwilling or unable to give informed consent - Secondary parkinsonism (e.g., drug induced) - Parkinson-plus syndromes - History of brain surgery for PD such as deep brain stimulation - No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects who have hypertension, diabetes mellitus, depression, or other common age-related illness will be included if their disease under control with stable treatment regimen for at least 30 days. - Neurogenic orthostatic hypotension defined as symptomatic decrease in BP > 20mmHg systolic or > 10mmHg diastolic and HR increase < 20bpm on supine to sitting or standing. - Clinically significant traumatic brain injury or post-traumatic stress disorder - Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study - Presence of dementia per Movement Disorder Society Level I criteria - Major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neuropathy assessment in the opinion of the responsible site principal investigator. - Subjects with clinically significant depression as determined by a Beck Depression Inventory score greater than 21 at the screening visit - Current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) - If the participant has a Beck Anxiety Score greater than 22 at the initial screening visit. - History of exposure to typical or atypical antipsychotics or other dopamine blocking agents within 6 months prior to the baseline visit - Use of investigational drugs within 30 days before screening - Subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to the baseline visit - Use of doxazosin, alfuzosin, prazosin, or tamsulosin - For female participant, pregnancy, or plans for child-bearing during study period - Participant is restricted from traveling to and from the study site

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Terazosin 5 MG
5 milligrams by mouth daily at bedtime
Placebo oral capsule
1 capsule by mouth daily at bedtime

Locations

Country Name City State
United States University of Iowa Hospitals and Clinics Iowa City Iowa

Sponsors (2)

Lead Sponsor Collaborator
Jordan Schultz University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Intervention-related Adverse Events Between Treatment Arms All patient-reported adverse events will be determine to be related to the study intervention by the site investigator. 12 weeks
Primary Incidence of Falls Between Treatment Arms The number of participants in each group who report a fall, as determined by the site investigator, will be reported. 12 weeks
Primary Frequency of Drop-out From Study/Discontinuation of Study Intervention for Any Reason The number of participants in each group who drop out of the study for any reason will be compared. 12 weeks
Secondary To Assess the Mean Change in Blood Pressure Mean change in sitting systolic blood pressure and diastolic blood pressure from baseline reading at 2 weeks, 6 weeks, and 12 weeks. A negative number indicates a decrease in blood pressure while a positive number indicates an increase in blood pressure. At Baseline, 2 weeks, 6 weeks, and 12 weeks
Secondary Number of Participants With Intolerable Side Effects How many participants discontinued study as a result of intolerable adverse events that were deemed to be medication-related. 12 weeks
Secondary Participants Demonstrating Non-Compliance All participants will be asked to bring their study intervention bottles to their 6 week visit and their 12 week visit so the Investigational Drug Pharmacy can count remaining pills and assess compliance based on dispensing history. A participant will be considered non-compliant if they had more than 5 missed doses during the course of the study. At 2 weeks, 6 weeks and 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A